For the second consecutive year, Quintiles has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress, the awards recognize and celebrate individuals, organizations and initiatives which have made significant contributions over the past 12 months.

The Best CRO award is presented to the honored CRO following two rounds of evaluation. First, customers vote for their preferred CRO online prior to the World Vaccine Congress to arrive at a list of five companies per category. Then, a judging panel makes its selection based on information provided in the following criteria: Range of services provided in niche and core therapeutic areas; methods of performance improvement or introduction of new services; attention to and quality of relationships with clients; reaching of milestones and final/ongoing outcomes; and building and maintaining existing and long-term partnerships.

“We’re proud to be recognized by our customers and peers as the Best CRO,” said Dr. Christopher Cabell, senior vice president, therapeutic delivery unit, Quintiles. “We work every day to advance the development of quality vaccines and anti-infective products. This achievement celebrates our commitment to create a healthier world.”

Quintiles is a provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. The company helped develop or commercialize 73% (11 of 15) of 2011’s best selling vaccine products or compounds.